for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Health News

Relief Therapeutics says 150 enrolled in COVID drug trial

ZURICH (Reuters) - Relief Therapeutics and partner NeuroRx Inc announced on Friday that 150 patients had been enrolled to date in a phase 2b/3 trial of RLF-100 for treating respiratory failure in patients with critical COVID-19.

Relief also said its main shareholder, GEM Global Yield LLC SCS, had exercised 500 million warrants in the company, putting Relief’s available cash balance at around 49.8 million Swiss francs ($54.5 million).

($1 = 0.9144 Swiss francs)

Reporting by Michael Shields; Editing by Caroline Copley

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up